Capital Planning Advisors LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Capital Planning Advisors LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 9.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 36,783 shares of the company’s stock after selling 3,700 shares during the period. Johnson & Johnson accounts for about 1.4% of Capital Planning Advisors LLC’s portfolio, making the stock its 19th largest position. Capital Planning Advisors LLC’s holdings in Johnson & Johnson were worth $4,759,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Virtus ETF Advisers LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth about $25,000. Krane Funds Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth $26,000. Financial Advantage Inc. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $28,000. Crewe Advisors LLC lifted its position in shares of Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares during the last quarter. Finally, Eii Capital Management Inc. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth $39,000. Institutional investors and hedge funds own 72.22% of the company’s stock.

Shares of NYSE:JNJ opened at $130.96 on Friday. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The company has a 50-day simple moving average of $130.86 and a 200-day simple moving average of $133.87. The stock has a market capitalization of $347.35 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 2.23 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.90%. Johnson & Johnson’s payout ratio is currently 46.45%.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a research report on Thursday, October 17th. Wells Fargo & Co decreased their price objective on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Raymond James decreased their price objective on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.